Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C1275122 (TEM)
 21,810 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Since resistance to several oral antimicrobials useful for the treatment of pediatric urinary tract infections (UTI) is overwhelming in Argentina, an in vitro investigation was performed testing 400 isolates obtained from urines of children suffering UTI's, 200 collected in 1990 and 200 in 1991. Their susceptibility against oral antimicrobials marketed in Argentina and appropriate for the treatment of UTI was determined by the agar dilution methods. An increase of the resistance to aminopenicillin combined with beta-lactamase inhibitors and to fluoroquinolones was observed comparing the two periods. Cefpodoxime (CPD), cefixime and fluoroquinolones except norfloxacin were the sole oral antimicrobials showing in vitro activity at the 90 per cent level. Unfortunately fluoroquinolones are not yet approved for pediatric use. Consequently we realized an in vitro and in vivo pharmacokinetic study in order to determine CPD activity against E. coli isolated in UTI cases. Five children (6-10 y) showing E. coli UTI infections received 10 mg/kg/d CPD in a single oral daily dose and were treated up to 10 days, 3 had lower UTI and 2 upper UTI. All patients were clinical and bacteriologically cured. Cultures obtained up to 4 weeks after treatment were negative. CPD serum levels at 2 hours after the first dose of treatment showed a median of 2.7 mg/l (2.3-3.4 range). Bactericidal serum titers at the same time against the patients own strain and an E. coli TEM-1 hyperproducer strain (MIC 4,096 mg/l for ampicillin and 0.5 mg/l for CPD) showed a median value of 1/8 against patients strains and 1/2 against the THP strain.(ABSTRACT TRUNCATED AT 250 WORDS)
 ...
PMID:Serum and urinary cefpodoxime levels and time killing curves performed in the urine of children presenting urinary tract infections. 823 40

Five per cent of Escherichia coli and klebsiella septicaemia isolates from the European Study Group on Antibiotic Resistance (ESGAR) study in 1987 to 1988 showed reduced susceptibility or resistance to cefotaxime, ceftazidime and/oraztreonam. Six of 15 isolates studied were susceptible to cefoxitin and MICs of cefuroxime, cefotaxime, ceftazidime and aztreonam were reduced by clavulanic acid. The isoelectric points of their beta-lactamases were in the range of 5.3-7.6. DNA hybridization showed that four of these beta-lactamases belonged to the TEM or SHV family. Transfer of cefotaxime resistance by conjugation was seen in two of the strains. Nine strains were resistant to cefoxitin (MIC > 16 mg/L) and MICs of cefuroxime, cefotaxime, ceftazidime and aztreonam were only slightly reduced in the presence of clavulanic acid. All nine strains produced at least one beta-lactamase of chromosomal origin with pI > 8.4, and four of these strains also harboured beta-lactamases with a pI range of 6.6-8.2. Cefoxitin resistance could be transferred by conjugation in one strain. Thus E. coli and Klebsiella spp. from the ESGAR septicaemia isolates were found to produce extended-spectrum beta-lactamases of both chromosomal and plasmid origin.
 ...
PMID:Extended-spectrum beta-lactamases in Escherichia coli and Klebsiella spp. in European septicaemia isolates. 828 97

During a multicentre study performed in 26 French hospitals, 287 (3.2%) of 9038 Enterobacteriaceae isolated, mainly Enterobacter spp., Serratia spp., Citrobacter spp. and Klebsiella spp. were classified as ceftriaxone resistant on the basis of an MIC > 4 mg/L or the presence of an extended-spectrum beta-lactamase. Extended-spectrum beta-lactamase was present mainly in Klebsiella pneumoniae (65 strains, 10.2%) and very rarely in Escherichia coli, Proteus mirabilis, Klebsiella oxytoca, Citrobacter spp. and Enterobacter spp. The extended-spectrum beta-lactamases conferred low-level resistance to ceftriaxone in nearly 60% of the strains harbouring them, emphasizing the need for routine testing for the presence of these enzymes. Among transconjugants three types of extended-spectrum beta-lactamase were identified. Those resembling TEM-3 were the most common, but TEM-21, and SHV-4 were also found. Clavulanate and to a lesser extent sulbactam inhibited all the extended-spectrum beta-lactamases encountered in this study.
 ...
PMID:Characterization of ceftriaxone-resistant Enterobacteriaceae: a multicentre study in 26 French hospitals. Vigil'Roc Study Group. 828 1

Since 1985 to 1990, 153 isolates of non typhoidic Salmonella were recovered from pediatric unit of the Charles Nicolle Hospital in Tunis. The epidemiological profile of these isolates was established according to the biochemical and serological characterizations, the antibiotic susceptibility patterns (disk diffusion method) to betalactams and aminoglycosides. 127 isolates of Salmonella spp were from stools and 22 from blood cultures. The main serotypes were S. ser. Wien (108 isolates) and S. ser. Typhimurium (21). A sample of 50 isolates was selected among the different resistance phenotypes for determination of MICs and betalactamase identification by isolelectro-focusing (36 isolates). All of them were resistant to ampicillin and carbenicillin but variable for cephaloridine. Since 1986 appeared the resistance to cefotaxime and in 1990 all the S. ser. Wien isolates were resistant to the 4 betalactams tested including cefotaxime associated to streptomycin, kanamycin, gentamicin, tobramycin and amikacin. All of them had a high level of resistance to amoxicillin and gentamicin (mean MICs > 2048 and > 512 mg/l). The mean MIC of cefotaxime was 43.2 mg/l for S. ser. Wien, 64mg/l for S. ser. Typhimurium and decreased to 1.9 and 0.12 mg/l in combination with 1 mg/l of clavulanic acid. The beta-lactam resistance was mediated to enzymatic mechanism, at first the betalactamase of TEM-1 type alone, then associated to extended-spectrum betalactamase, mainly type SHV-2 since 1986, and other new types in 1990. They were under the control of plasmids with different sizes.
 ...
PMID:[Epidemiological pattern of the resistance of 153 Salmonella strains (S. typhi excluded) isolated in a Tunisian pediatric unit from 1985 to 1990]. 829 Mar 17

The antimicrobial activity of cefpirome was compared with amoxycillin/clavulanic acid, ampicillin/sulbactam, cefuroxime, ceftazidime, gentamicin and amikacin against 743 non-duplicate clinical isolates. MIC50 and MIC90 showed that the antibiotic was active against both Gram-negative and Gram-positive organisms. Cefpirome was highly active against most of the Enterobacteriaceae, including indole-positive Proteus spp., Aeromonas spp. (MIC < or = 1 mg/L) and Salmonella spp. (MIC < or = 0.5 mg/L). Neisseria gonorrhoeae and Haemophilus influenzae (including beta-lactamase producers) were all susceptible, with MIC less than 0.5 and 0.25 mg/L respectively. Cefpirome was more active than cefuroxime and ceftazidime against Campylobacter spp. (MIC < or = 2 mg/L), but less active than ceftazidime against Pseudomonas aeruginosa. Cefpirome was active against Streptococcus pneumoniae. Streptococcus bovis and coagulase-negative staphylococci (MIC < or = 0.5 mg/L) and methicillin-sensitive Staphylococcus aureus (MIC < or = 2 mg/L). Methicillin-resistant S. aureus, Gram-positive and Gram-negative anaerobes were resistant to cefpirome. The stability of cefpirome to TEM-1, TEM-2, PSE-1, SHV-1 and the chromosomal-mediated P99 and K-1 beta-lactamases was comparable to ceftazidime.
 ...
PMID:The antimicrobial activity and beta-lactamase stability of cefpirome, a new fourth-generation cephalosporin in comparison with other agents. 833 98

Shigellae are the most frequently isolated invasive bacteria in Djibouti. 140 clinical strains collected during an eight months period have been studied for their in vitro susceptibility to antibiotics mainly used in treatment and prophylaxis by measure of MIC (agar dilution) for all antibiotics except for trimethoprim-sulfamethoxazole, trimethoprim and sulfamethoxazole (disk diffusion on lysed horse blood medium). Characterization of beta-lactamase is carried out for all strains resistant to amoxicillin and for all S. sonnei. The overall prevalence of resistance to amoxicillin is 41.7% (penicillinase TEM-1, OXA-1 and OXA-3 alone or associated) to tetracyclines 97.1% and to trimethoprim-sulfamethoxazole 51.4%. This prevalence is particularly high for amoxicillin with S. flexneri and for trimethoprim-sulfamethoxazole with S. sonnei. All strains of S. sonnei have a low level chromosomal cephalosporinase without phenotypic expression. Among 68 strains sensitive to trimethoprim-sulfamethoxazole, 39 are resistant to sulfamethoxazole alone. All strains are sensitive to nalidixic acid and fluoroquinolones. These data allows us to recommend fluoroquinolones for treatment and prophylaxis of shigellosis in Djibouti.
 ...
PMID:[Antibiotic sensitivity of 140 strains of Shigella isolated in Djibouti]. 838 18

We investigated the in vitro activity and the in vivo efficacy of the beta-lactam-beta-lactamase inhibitor combination cefoperazone-sulbactam against an isogenic series of Klebsiella pneumoniae strains. Both cefoperazone and cefoperazone-sulbactam were active in vitro against a susceptible clinical strain, and the combination was highly effective in the treatment of rat intra-abdominal abscesses. Loss of expression of a 39-kDa outer membrane protein resulted in at least a fourfold increase in the MICs of cefoperazone and cefoperazone-sulbactam but did not appreciably affect the in vivo efficacy of either regimen. Introduction of plasmid RP4, which encodes the TEM-2 beta-lactamase, into the susceptible strain resulted in the loss of in vitro activity and in vivo efficacy for cefoperazone. The in vitro activity of cefoperazone-sulbactam against this strain was diminished, but the antibiotic combination remained highly active in vivo. Introduction of RP4 into the strain lacking the 39-kDa outer membrane protein resulted in a fourfold increase in the in vitro MIC of cefoperazone-sulbactam in comparison with the beta-lactamase-producing susceptible strain and resulted in a loss of in vivo efficacy against infections caused by this strain. These results suggest that the combination of different resistance mechanisms, neither of which alone results in substantially diminished cefoperazone-sulbactam efficacy in vivo, can cause in vivo resistance to the beta-lactam-beta-lactamase inhibitor combination in K. pneumoniae.
 ...
PMID:Resistance to cefoperazone-sulbactam in Klebsiella pneumoniae: evidence for enhanced resistance resulting from the coexistence of two different resistance mechanisms. 839 Aug 9

The in vitro activity of FK-037, 5-amino-2-[[(6R, 7R)-7-[[(Z)-2-(2-amino-4-thiazolyl)-2- methoxyimino) acetyl] amino]-2-carboxy-8-oxo-5-thia-1- azabicyclo[4.2.0]oct-2-en-3-yl]methyl]-1-(2-hydroxyethyl)-1H-pyrazoli um hydroxide, inner salt, sulfate (1:1), a new parenteral cephem, was compared with those of cefepime, ceftazidime, imipenem, and ciprofloxacin. FK-037 inhibited methicillin-susceptible staphylocci at < or = 4 micrograms/ml. Of 98 isolates of homogenous methicillin-resistant Staphylococcus aureus, 55 (56.1%) were inhibited by 8 micrograms of FK-037 per ml, compared to 3.1% for cefepime. Imipenem was the most active beta-lactam tested against staphylococci. The MIC of FK-037 for 90% of the strains tested (MIC90) was 0.06 micrograms/ml for hemolytic streptococci, Streptococcus pneumoniae, viridans group streptococci, and Streptococcus bovis. The MIC90 for many of the members of the family Enterobacteriaceae was 1 microgram/ml, similar to that of cefepime and lower than those of ceftazidime and imipenem. The MIC90 for Klebsiella pneumoniae and Enterobacter cloacae was 8 micrograms/ml, similar to that for cefepime, but all isolates were inhibited by 2 micrograms of imipenem per ml. K. pneumoniae isolates with cefotaxime and ceftazidime MICs of > 32 micrograms/ml with Bush type 2b' beta-lactamases were inhibited by 4 micrograms of FK-037 per ml. E. cloacae, Citrobacter freundii, and S. aureus stably resistant to FK-037 could be selected by repeated transfer in the presence of FK-037. The FK-037 MIC90 for Pseudomonas aeruginosa was 4 microgram/ml, compared to 32 microgram/ml for cefepime and ceftazidime and 8 microgram/ml for imipenem. Xanthomonas maltophilia, Pseudomonas cepacia, Acinetobacter anitratus, and Bacteroides species were resistant to FK-037 (MIC, more than or equal 32 microgram/ml). MBCs were identical to or within twofold of the MICs except for a 32-fold greater MBC for P. aeruginosa. Inoculum size and acid environment did not lower the activity of FK-037. FK-037 was not appreciably hydrolyzed by Bush group 1, 2a, 2b, and 2e beta-lactamases but was hydrolyzed by 2b' and 2d enzymes at rates comparable to that of ceftazidime. Nonetheless, FK-037 inhibited bacteria possessing TEM-3, -5, and -7 and SHV -5 at less than or equal 8 microgram/ml. Overall, FK-037 has lower MICs against staphylococci and P. aeruginosa than the currently available iminomethoxy aminothiazolyl cephalosporins and has activity against members of the family Enterobacteriaceae comparable to that of cefepime.
 ...
PMID:In vitro activity and beta-lactamase stability of FK-037, a parenteral cephalosporin. 846 Sep 25

Ten extended spectrum beta-lactamases producing strains of Klebsiella pneumoniae characterized by analytical isoelectric focusing and studied for their susceptibility to beta-lactam antibiotics, either alone or in combination with a beta-lactamase inhibitor (clavulanic acid and sulbactam) and in association with amikacin. The extended spectrum beta-lactamases were derived from either TEM (CTX-1 = TEM-3) or SHV (CAZ-4 = SHV-5). Killing curves were studied with antibiotics at clinical by achievable concentrations, at MIC and MIC x 4. At MIC, cefotetan, cefotaxime and ceftazidime lacked bactericidal activity. Imipenem was more rapidly bactericidal than meropenem or co-amoxiclav. At MIC x 4, cefotetan and cefotaxime exhibited bactericidal effect but this was less than for imipenem which gave a reduction of 4 log10 of the inoculum. Cefotaxime plus sulbactam gave no bactericidal effect compared with cefotaxime plus co-amoxiclav. A bactericidal effect with cefotaxime plus sulbactam was seen with the addition of amikacin. At clinical concentrations cefotaxime plus co-amoxiclav +/- amikacin was as efficient as imipenem +/- amikacin with a rapid bactericidal effect (5-6 log10 in 30-60 min). We proposed that cefotaxime+co-amoxiclav might be considered as an alternative to imipenem for the treatment of extended spectrum beta-lactamase associated K. pneumoniae injections.
 ...
PMID:Bactericidal effect of beta-lactams and amikacin alone or in association against Klebsiella pneumoniae producing extended spectrum beta-lactamase. 853 74

The beta-lactamases of six strains of Acinetobacter baumannii were investigated using analytical isoelectric focusing, and the MIC values for 16 beta-lactam antibiotics determined against the strains. Three strains produced a chromosomal cephalosporinase (pI > 8.5), one strain a CARB-5 beta-lactamase (pI = 6.35), one strain a TEM-1 penicillinase (pI = 5.4) as well as a cephalosporinase (pI > 8.5), and one carbapenem-resistant strain a beta-lactamase with a pI > 8.5. Ceftazidime, cefepime, cefpirome, imipenem and meropenem were found to be the most effective beta-lactams against five strains. Sulbactam was active against four of the strains at 1-4 mg/L and showed enhanced killing effects with cefpirome.
 ...
PMID:In-vitro activity of cephalosporins alone and combined with sulbactam against various strains of Acinetobacter baumannii with different antibiotic resistance profiles. 864 58


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>